Clinical Trial

Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study

Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy, targeted therapy,loco-regional treatments ) in patients with bile duct cancer. The effectiveness and tolerance of these treatments in current practice will also be evaluated.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-06-15; most recent amendment 2025-07-22.
Status change: Not Yet Recruiting → Recruiting 2023-02-28
Trial Details
NCT Number NCT04935853
Lead Sponsor GERCOR - Multidisciplinary Oncology Cooperative Group
Conditions Biliary Tract Cancer
Enrollment 1,350 participants
Start Date 2022-05-23
Primary Completion 2030-06-01 (estimated)
Study Completion 2040-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-23